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ABSTRACT
Introduction
A comprehensive respiratory panel (CRP) is a quick and non-invasive laboratory diagnostic test
that can detect viral nucleic acids by utilizing polymerase chain reactions (PCR). A CRP can
detect multiple causative agents associated with upper respiratory illness and CRPs are
commonly used in the Kentucky Children’s Hospital as part of the initial evaluation for patients
who present with signs and symptoms of a respiratory infection. While CRPs are quick to detect
the presence of a viral illness and are shown to increase the prescribing of antivirals for viral
illnesses, the cost of the CRP to the hospital is around $130, and the cost to patients is even
more. There is no published literature that analyzes the cost of CRPs when considering the price
of the test, the change in length of stay, and the potential cost savings of antibiotic
discontinuations related to positive PCR results.
Methods
The study was a chart review of pediatric patients, one day to 18 years old, who received a
comprehensive respiratory panel diagnostic test for a suspected respiratory illness while
admitted to the Kentucky Children’s Hospital (KCH) between October 1, 2016 and April 30,
2018. Patients were identified via ICD-9 or ICD-10 codes for respiratory illness during the study
time frame. Other data that were collected include antibiotic use, length of stay, and
comprehensive respiratory panel results. The cost analysis was completed by comparing the
cost and use of the CRP to the direct, indirect and total costs of hospitalization.
Results
A total of 355 patients comprised the study population. Only 20.2% (N=72) of patients received
a CRP and of those CRPs 75% (N=54) were positive for viral analytes. The median total cost of
admission for the study population was $3,623.07. Patients with a CRP had significantly higher
direct, indirect, and total costs (p<0.05). The median length of stay (two days) was the same in
those with or without CRPs.
Conclusions
Overall, patients admitted to KCH who received CRPs had greater costs than those who did not.
Furthermore, there was no significant difference in the median length of stay between those
with or without CRPs. The study shows ways that healthcare costs can be diminished through
policy development and public health initiatives around culture stewardship.

Keywords: Comprehensive Respiratory Panel, Cost Analysis, Pediatrics
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INTRODUCTION
A comprehensive respiratory panel (CRP) is a quick laboratory diagnostic test that can
detect viral nucleic acids by utilizing polymerase chain reactions (PCR). A CRP can detect
multiple causative organisms associated with upper respiratory illness, including but not limited
to adenovirus, influenza A, influenza B, rhinovirus/enterovirus, and atypical bacterium. For this
reason, CRPs are commonly used in the Kentucky Children’s Hospital as part of the initial
evaluation for patients who present with signs and symptoms of a respiratory infection.
According to McCulloh and colleagues, CRPs are congruent with more appropriate use
of antivirals in patients with positive CRP results as well as increased prescribing of antibiotics in
children with a negative CRP1. Another study evaluated the average length of stay and use of
antibiotics when CRPs were utilized in comparison to patients who did receive a CRP. The
authors of this study concluded that even with a shorter turnaround time, there was not a
significant difference between antibiotic use and length of stay in the two groups2.
While CRPs are quick to detect the presence of a viral illness and are shown to increase
the prescribing of antivirals for viral illnesses, the direct cost of the CRP to the hospital is around
$130 per test and can cost the patients even more. Currently, there is no published literature
that analyzes the cost of CRPs when considering the price of the test, the change in length of
stay, and the potential cost savings of antibiotic discontinuations related to positive PCR
results.
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Literature Review
The purpose of the literature review was to analyze previous publications over the use
of comprehensive respiratory panels within children hospitals and to understand the
implications on health care spending and clinical outcomes. The primary literature search and
review was completed via PubMed searches of keywords and sifted for relevancy and
timeliness. The goal was to formulate specific research questions and to fill gaps in current
knowledge and clinical practice.
Historically, respiratory disorders and infections are one of the top three reasons for
pediatric visits to emergency departments and hospitalizations4. According to a 2014 statistical
brief over hospital stays for children in the United States from the Healthcare Cost and
Utilization Project , respiratory conditions accounted for twenty-two percent of all
hospitalizations in nonneonates5. Furthermore, upper respiratory tract infections (URTIs) are
the most frequent infection in children throughout the industrialized world and on average a
child will have six to ten URTIs during a calendar year6. U.S. healthcare spending on respiratory
conditions remains one of the largest expenditures. In 2013 alone, one hundred and sixty-one
billion dollars were spent on respiratory conditions, and this category accounts for eight
percent of total healthcare spending7.
Thus, understanding what an acute respiratory illness is and how it is diagnosed and
treated can prove valuable in navigating pediatric care. Acute respiratory illnesses (ARI) occur in
either the upper or lower respiratory tracts (LRTs). The upper respiratory tract extends from the
nasal passage to the larynx, and the lower respiratory tract encompasses the trachea and
bronchi to the bronchioles and alveoli8.
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Symptoms of acute respiratory illnesses depend on the site of infection and causative
agent. Upper respiratory tract infections are characterized by rhinorrhea, cough, sneezing, and
hoarseness; whereas LRTIs are characterized by tachypnea, wheezing, severe cough,
breathlessness, and respiratory distress3. Overall, the management of most acute respiratory
illnesses is supportive care and the disease course is self-limiting. Rarely are medications
prescribed, and most can be treated via symptom management and over the counter products.
Therefore, clinical diagnoses are based on the patient’s past medical history and symptom
presentation. Diagnostic testing is rarely used, especially in the community setting, for
diagnoses of ARI. However, when symptoms are associated with acute bronchitis9, pneumonia,
sepsis or prolonged symptoms without improvement, clinicians may choose to perform a CRP
diagnostic test to understand the conditions’ specific etiology.
The largest etiology of ARI is viruses. Rhinoviruses account for a quarter of all URTIs.
Whereas respiratory syncytial viruses, influenza viruses, human metapneumovirus,
and adenoviruses account for 25 to 35 percent, and coronaviruses account for ten percent of
upper respiratory illnesses10. While CRP PCRs have high sensitivity for respiratory syncytial virus
and influenza viruses in children with ARI, there is a low specificity for many other
respiratory pathogens. Test results must therefore be interpreted with caution11.
According to the Journal of Clinical Microbiology, the past decade has seen vast
improvements in the accuracy and availability of respiratory virus testing12, and with improved
reliability there has been increased usage. However, guidelines are not clear as to which
patients need to receive a comprehensive respiratory panel diagnostic test. A Dutch study
found that, in pediatrics, upper respiratory infections are so common that acute and prior
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infections with adenoviruses and rhinoviruses cannot be distinguished by PCRs. The study
concluded that optimal usage of respiratory PCRs would be to distinguish bacterial
superinfections from viral infections11. It seems that most published literature concludes that in
current practice the most appropriate usage of comprehensive respiratory panels in pediatric
patients is in those with severely immunocompromised systems or to rule out severe bacterial
infections in patients with prolonged acute respiratory illnesses (>5-7 days). Many clinicians did
not see improvements in clinical outcomes with the use of CRP. As to be expected with current
practice and literature, the highest usage of CRPs in children’s hospitals occur in the pediatric
intensive care units (PICU)13. This is because of the level of critical care required by these
patients. Many practitioners believe CRPS can aide in the reduction of nosocomial infections as
this is a required PICU benchmark. In a 2019 study published in Pediatric Critical Care Medicine,
it was found in a tertiary PICU that patients with positive respiratory PCR results versus patients
with negative findings did not experience longer intubation days or decreased clinical
outcomes. The report’s conclusion challenges the clinical value of viral respiratory diagnostics in
PICU patients13.
As more and more studies show there is no improvement in clinical outcomes such as
survival, intubation days, and extra corporeal support, researchers began to turn their attention
to government supported benchmarks as primary outcomes. Since 2009, the Department for
Human Health and Services (HHS) has made the prevention of hospital-acquired infections (HAI)
and antimicrobial resistance a top U.S. public health initiative14. The Role of a Respiratory Viral
Panel in the Clinical Management of Pediatric Inpatients found that in a retrospective chart
review of pediatric patients at a tertiary children’s hospital, patients with a positive respiratory

8

viral panel (RVP) had decreased use of intravenous antibiotics15. Furthermore, McCulloh, et al.,
found that children with a positive RVP result received antibiotics less often (51.6% versus
67.0%; P = .003) than those with a negative RVP. The study concluded that RVPs are beneficial
to physician decision-making when prescribing antimicrobials1. While the previous two studies
were conducted in pediatrics, adult data also conclude the same information. Hospital
Pharmacy published a retrospective chart review in October 2017, which demonstrated no
significant change in duration of antibiotics16 in adult patients with CRPs.
In addition to antimicrobial stewardship, another core measure of hospital success and
reimbursement is length of stay. Generally, length of stay is measured in number of hospital
days as decided by institution-specific protocols. The Centers for Medicare and Medicaid use
length of stay as a core component of hospital reimbursement. This stems from research that
shows an increased length of stay is associated with HAI, increased costs and increased
mortality. Thus, researchers have explored the implications that CRPs have on the average
length of stay. According to, Impact of Respiratory Viral Panel Polymerase Chain Reaction Assay
Turnaround Time on Length of Stay and Antibiotic Use in Patients With Respiratory Viral
Illnesses, there was no significant difference between the average length of stays in those that
receive PCRs and those that did not16. This seems to be the overall conclusion of the published
data. Furthermore, there is no significant difference in the type of PCR performed and the
average length of stay17.
All in all, there is a plethora of data surrounding antibiotic usage, length of stay, and
comprehensive respiratory panels. However, current literature contains gaps in knowledge
when it comes to the financial analysis of the costs of the panels, antibiotics, and length of stay.
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If there is no decrease in length of stay, does the cost of the CRP PCR validate the clinical
outcome? By analyzing the cost of comprehensive respiratory panels with the cost of length of
stay, this research will guide clinicians to appropriate CRP stewardship and protocols. In
addition, by descriptively analyzing antimicrobial usage, this study will be a tipping point for the
financial analysis of antibiotics and comprehensive respiratory panels. This research will be
beneficial to both hospital pharmacy and public health practice, as the objective of this study
was to evaluate the cost associated with comprehensive respiratory panel use in pediatric
patients at Kentucky Children’s Hospital with upper respiratory illness. The long-term goal will
to be to create new hospital policies to decrease healthcare costs and improve patient
outcomes with the study’s results.
METHODS
Study Design Overview
This study was an IRB approved retrospective chart review of pediatric patients, one day
to 18 years old who were admitted to Kentucky Children’s Hospital between October 1, 2016
and April 30, 2018, for an acute respiratory illness. Patients were identified via ICD-9 or -10
codes for respiratory illness during the study time frame. If a patient has multiple visits within
the time frame, all their visits were included in this study. Collected data included
comprehensive respiratory panel diagnostic testing, comprehensive respiratory panel results,
antibiotic use, length of stay data, and hospital admission costs. Costs were determined utilizing
the direct, indirect, and total cost of admission for the patient. Patient payment structure and
total charge to insurance were not be included in the analysis. The cost analysis was be
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completed by comparing the cost associated with the CRP with the costs of hospital admissions
and length of stay.
Study Population
The study population evaluated was pediatric patients ages one day to 18 years old who
were admitted for respiratory illness at the Kentucky Children’s Hospital from October 1, 2016
through April 30, 2018. A patient’s data was used multiple times if they have multiple hospital
visits during the intended study duration. Patients greater than or equal to 19 years old were
excluded from the study, as they are no longer pediatric patients. Furthermore, antibiotic
therapy was excluded if it was indicated for any diagnoses besides a respiratory illness. Patients
were also excluded from this study if they were not admitted to KCHs and did not have an
inpatient status, or if they were admitted to the Neonatal Intensive Care Unit. There were no
other exclusions based on other disease states, gender, or race.
Exposures and Outcomes
The primary exposures of this study were acute respiratory illnesses and CRP testing.
The study then evaluated the outcomes of the following research questions by using length of
stay, antibiotic use, CRP results, and cost data. First, do patients with an upper respiratory
illness at KCH that receive a CRP have higher direct costs than those that do not receive CRP
testing? In turn, do patients that receive CRP testing have higher total costs for admission than
those that do not receive testing? Next, do patients that receive CRP diagnostic testing also get
antibiotic therapy? Finally, do patients diagnosed with an ARI at KCH that receive a
comprehensive respiratory panel (CRP) have the same LOS compared to those that do not
receive CRP testing?
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Statistical Analysis
The study population was characterized by descriptive statistics. Pearson’s Chi-squared
test was used to evaluate the effect of gender on comprehensive respiratory panel testing, as
both are categorical values. To analyze the significance of CRP testing on costs and the
significance of CRP testing on length of stay, non-parametric methods were utilized due to the
skewed nature of cost and length of stay values. Thus, the differences of medians were chosen.
The differences of medians were also computed to understand the effect of antibiotic usage on
costs. Finally to understand the relationship between cost and length of stay, liner regression
was used to analyze the variables. P-values less than 0.05 were considered statistically
significant. All statistical testing was performed using BM SPSS Statistics version 23.
RESULTS
Between October 1, 2016, and April 30, 2018, 17,778 patients were admitted to
Kentucky Children’s Hospital. Of these patients, 355 patients had ICD-9 and ICD-10 codes
consistent with an acute respiratory illness and were included as subjects in the study. The
average age of participants was 2.73 years of age, and ages ranged from 13 days of life to 17
years of age. Of the participants 42.8% (N=152) were female and 57.2% (N= 203) were male. Of
the 355 patients included in the study, only 20.2% (N=72) received a CRP PCR. Of note, two
patients did not receive a CRP, because the test was a duplicate order and was cancelled by the
physician. Antibiotic therapy was initiated in 20.2% (N=72) of patients in the study group, and
the median LOS for participants was two hospital days, with values ranging from zero days to
forty-four days.
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Within the 72 patients that received a comprehensive respiratory panel, 75% (N=54)
were positive results; where as 25% (N=18) were negative for all analytes. The most common
positive result from the CRP was rhinovirus/enterovirus (52.8%,N=38). The least common
positive result was for bacteria isolates (0%, N=0). The frequencies for the other results are
displayed in Figure 1. A Pearson’s Chi-squared test was performed to analyze if sex had a
relationship to a patient receiving a CRP. With a p-value of 0.069, there was no statistically
significant relationship between sex and receiving a comprehensive respiratory panel.
Due to outliers within the three cost data categories (direct cost, indirect cost, and total
cost) and the LOS values, the nonparametric differences of medians test was used to evaluate
the relationship between cost, comprehensive respiratory panels and LOS. A total of 353 of the
355 patients were included in the analysis two were excluded because they did not have cost or
LOS data associated with their patient code identifier. The medians of LOS were not statistically
significant for the 72 patients that received a CRP (median =2, p-value =0.064). However, the
medians for the cost data were significantly different for patients that received a CRP and those
that did not. The median direct cost for patients without a CRP was $2,006.74 and the median
direct cost for patient with a CRP was $2,726.64 (p-value =0.011).The median indirect cost for
patients without a CRP was $1385.27 and the median direct cost for patients with a CRP was
$1,957.05 (p-value =0.023).Finally, the median total cost was $3,398.72 for patients without a
CRP and for patients with a CRP the total cost was $4,504.01 (p-value =0.011). A breakdown of
cost data in relation to CRP diagnostic testing is displayed in Figure 2. Figures 8-11 contain LOS
and cost data measures of dispersion.
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Of 74 patients that were given antibiotic therapy while admitted, 9.7% (N=7) received
antibiotics for a respiratory indication. The prescribed antibiotics in this category were
Amoxicillin-clavulanate, Ceftriaxone, Amoxicillin, Cefdinir, and Ampicillin. Ampicillin and
Amoxicillin were the most commonly ordered (57.1%, N=4). If a patient did not have a CRP then
they did not have antibiotic use (100%, N=283). Of the seven patients that received antibiotics,
while admitted, 100% (N=7) had CRP cultures positive for a viral analyte. To analyze antibiotic
use and cost data, the non-parametric test of medians was used. The median direct cost (pvalue=0.008), the median indirect cost (p-value=0.040), and median total cost (p-value=0.025)
were statistically different between patients that received antibiotics and those that did not.
Refer to Figure 3 for a full breakdown of antibiotic use in relationship to cost. However the
median length of stay was not significantly different between those that received antibiotics
and those that did not (p-value=0.102).
Finally, the relationship was analyzed between LOS and total costs. As previously
mentioned, the median length of stay was two hospital days. The median direct cost was
$2,115.98. The median indirect cost was $1,455.54, and the median total cost was $3,623.07.
To understand the relationship between length of stay and total cost a univariate linear
regression was performed. The R value was 0.928 and the R2 value was 0.860. This was a
statistically significant relationship with a p-value of 0.00.
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DISCUSSION
To address the current role of comprehensive respiratory panels in pediatric acute
respiratory illnesses, this study examined the frequency of CRP tests and the effect of CRPs on
LOS, antibiotic use, and patient costs.
The study population was very similar to many of the studies previously published on
comprehensive respiratory panel use in pediatric patients and respiratory illnesses in children.
ARIs are most common in children less than five years of age8. In addition, overall incidence of
acute respiratory illnesses are higher in males, and male sex is a risk factor for having more
severe disease requiring hospital admission17. The study population’s average age of 2.73 years
and 57.2% (N=203) male distribution aligns with expected results. This is an indication that the
study population is a sample reflective of pediatric ARIs in the United States, and that the study
may have applications to other children’s hospitals with similar patient population distributions.
The frequency of CRPs was an unexpected result of this study. It was projected that
approximately 40% of the study population would have a CRP. However, the study resulted in
only 20% of patients receiving a CRP. In fact, previous studies demonstrated an incidence of
CRP testing at 46.8%1. Therefore, it is possible that the ICD-9 code used was not reflective of
every patient admitted to KCH with an ARI. This could be due to errors in coding and diagnosis,
and because lower respiratory tract infections were not included.
All in all, it is likely that CRPs are used more often than the study population concludes.
Despite the low prevalence of CRPs. The results of the CRPs were as expected. Most of the CRPs
were positive for all analytes. In addition, the most frequent isolate from positive tests was
rhino/enterovirus. These results are reflective of the incidence of these viruses in children10 and
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of CRP results from other studies1. This supports the validity of the data and the application of
previous studies to patients admitted to KCH. In addition, these results support the value of the
data collected, despite the low rate of CRPs.
The primary objective of the study was to evaluate the cost associated with
comprehensive respiratory panel use in pediatric patients at Kentucky Children’s Hospital with
upper respiratory illness. The null hypothesis was rejected for every difference of medians test
between cost variables and CRPs. This signifies that between patients with a CRP and those
without a CRP, the direct cost, indirect cost, and total cost are higher for patients that have a
CRP. Thus, it can be concluded that CRPs increase the total cost for patients admitted to KCH.
While many factors compose cost data, two of the largest contributors to cost data are
pharmacologic treatment and length of stay. In 2009 alone, 3.5 billion dollars were spent on
inpatient antibiotic therapy21. Thus, antibiotic usage and length of stay were also analyzed in
relation to CRPs and cost. It was unexpected that patients in the study population who received
antibiotics for respiratory illnesses all had CRP diagnostic testing. In fact previous studies have
shown that there is no statistical difference in antibiotic usage and prevalence of CRP testing1. A
possible explanation is that order sets in the hospital’s electronic medical record system are
responsible for this. When a physician selects a diagnosis, the EMR automatically orders the
CRP. Another possible explanation is that physician ordering of CRPs was related to the severity
of the patient’s illness. Thus, patients that had more severe symptoms received a CRP and a
course of antibiotics. However, it is important to note that none of the CRP tests were positive
for bacterial analytes, making antibiotic use obsolete in these patient cases.
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The difference of medians test showed that there is a significant relationship between
antibiotic use and direct, indirect and total costs. Patients who receive antibiotic therapy had
higher total costs. While the objectives of the study did not include analyzing the effect of CRPs
and the changes in antibiotic prescribing, this would be the next point of study from the
collected data. It would be interesting to know if there is a significant relationship between
CRPs and decreases in antimicrobial prescribing, especially since all of the patients that received
antibiotics tested positive for viral analytes.
Length of stay is another variable highly related to healthcare costs. The average length
of stay in the United States for patients aged 0-17 years is 4.0 hospital days19. This varies from
the 3.03-day average length of stay of the patients in this study. This is most likely attributed to
the exclusion of NICU patients in the study population because the average LOS in the NICU is
13.2 days. The study population’s average total cost was $6,787.73, compared to the national
average of $6,763.0019. So while length of stay is slightly different the average cost data is on
trend. This is why the linear relationship between total cost and length of stay was analyzed in
this study. The univariate linear regression between LOS and total cost computed an R-value of
0.982. Thus, there is a positive relationship between the two variables. As LOS increases so
does the total cost. As the median length of stay between the two study groups was not
statistically different (p>0.05), then the length of stay should not be the primary variable
attributed to the increase in costs in those that had CRPs. This supports the hypothesis that
patients who receive CRPs have increased costs.
Overall, the results of this study have far-reaching pharmacy and public health
implications. First, the results support evidence-based approaches to the management of acute
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respiratory illnesses in pediatric patients. The study supports that fact ARIs are primarily viral in
nature. Due to the lack of efficacy of antibiotics against viral infections, antibiotic resistance
may be fought by decreased antibiotic prescribing for ARIs. In fact, these infections can be
managed at home and without a hospital admission, as long as patients can stay hydrated and
nourished. Not only does the study support antimicrobial stewardship, but it also showcases
the relevance of culture stewardship. As culture stewardship is becoming the next hot topic in
healthcare, the study validates the ideas that getting a culture of any kind from a patient,
simply because a prescriber can, is not evidence-based medicine nor best practice. As can be
seen in the results of this study, the CRP results did not change the illness management for the
majority of the patients because the largest percentage of viral analytes were rhinovirus or
enterovirus. The treatment for rhinovirus and enterovirus infections is supportive care and
symptom management which may be managed with over-the-counter medications, hydration
and rest.
Above all, the results showcase ways to decrease healthcare expenditures. As rising
healthcare costs are one of the largest threats to improved public health and increased
healthcare access, decreasing the usage of CRPs can be a start for healthcare savings in
children’s hospitals. This can be accomplished through new hospital policy and by limiting the
access that physicians have to CRPs. At KCH, a CRP is part of the pediatric croup order set. By
removing the CRP from this order set and others like it, the prevalence of CRPs will decrease
which will save both the institution and patient healthcare dollars. Another way to decrease the
frequency of CRP would be to limit the tests to specific indications where it is clinically
beneficial, such as pediatric neutropenic fever. Ultimately, the results of this study conclude
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that comprehensive respiratory panels have virtually no function in ARI diagnosis, but a large
impact on the costs of healthcare.
Limitations
One of the primary limitations of the study is sample size. Despite the large number of
admissions to the Kentucky Children’s Hospital over the course of the study, only 355 patients
fit the study’s inclusion criteria and four of the patients were excluded in different parts of the
analysis due to a duplicate CRP order and missing cost/LOS data. This effects the generalizability
of the results. Including more ICD-9 and ICD-10 codes for other ARIs, such as LRTIs and
bronchiolitis, would mitigate this limitation and should be applied as future methodology to
similar studies. Another limitation of the study is time constraints. As with most literature on
this topic, the retrospective chart review of a single institution does not create the most
generalizable results to other patient populations. By creating a prospective cohort study, the
results would be more profound and reliable. The third limitation of this study is the skewed
nature of the cost and length of stay data. As can be seen in Figures 2 – 5 , the data included
large outliers. Thus, the cost and length of stay variables were right-skewed. The mean is larger
than the median for these data sets. To account for this, nonparametric difference of medians
tests were used to compare these dependent variables to the explanatory variables. Finally, the
largest limitation is the multiple factors that go into cost calculations. These factors include
pharmacologic therapy, length of stay, respiratory therapy, nutrition, ventilators, and
comorbidities. For more a more reliable financial analysis of the relationship between cost and
CRPs, a multivariate analysis should be included to account for correlated variables. This is
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especially important because both antibiotic use and CRPs were associated with increased costs
but not associated with increased length of stays.

CONCLUSION
In summary, comprehensive respiratory panels show increased overall costs when
utilized in patients admitted to Kentucky Children’s Hospital with the diagnosis of an acute
respiratory illness. In addition, CRPs did not decrease the length of stay for patients in the study
population. An interesting finding was that patients with CRPs had associated antibiotic use and
positive CRP results for viral analytes. This has opened the doors to evaluate the impact that
CRPs have on antibiotic prescribing and the associated financial expenditures or savings. Other
future research will be to find the appropriate place for CRPs in the treatment of pediatric
respiratory illnesses. This study has demonstrated that there is a financial burden associated
with the panels; however, it did not evaluate the clinical outcomes on morbidity and mortality
associated with CRP use.
Overall, the study filled the current gap in published literature regarding the financial
impact of comprehensive respiratory panels on healthcare costs. It has also confirmed previous
studies analyzing the prevalence and causative agents of acute respiratory illnesses. The public
health impact of the study will be decreased healthcare dollars. Ultimately, the study has
established relationships, but it will be up to public health officials and hospitals administrators
to create policies to cut CRP use and its associated financial burden through policy and
procedure development.
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APPENDIX
Figure 1: CRP Results
Result
Frequency

Rhino/Entero HMPV
52.8%
N=38

5.6%
N=4

Flu

RSV

Adeno Corona Paraflu Bacteria

0%
N=0

8.3%
N=6

6.9%
N=5

8.3%
N=6

9.7%
N=7

0%
N=0

Figure 2: Evaluation of CRP Diagnostic Testing and Cost
CRP
No

Measures of
Frequency

LOS

Direct Cost

Mean
Median
Sample Size
Standard Deviation
Minimum
Maximum

2.7
$3,775.40
2
$2,006.74
281
281
4.114
$7,948.86
0
$279.42
44 $108,254.78

Mean
Median
Sample Size
Standard Deviation
Minimum
Maximum

4.31
2
72
5.479
0
31

Mean
Median
Sample Size
Standard Deviation
Minimum
Maximum

3.03
$4,335.10
2
$2,115.98
353
353
4.465
$8,114.17
0
$279.42
44 $108,254.78

Indirect Cost

Total Cost

$2,208.94
$5,984.34
$1,385.27
$3,398.72
281
281
$4,206.30
$12053.71
$267.06
$546.48
$59,404.03 $167,658.82

Yes
$6,519.46
$3,403.74
$2,746.64
$1,957.05
72
72
$8,435.68
$3,830.35
$845.89 $536.5273
$45,513.61
$19,804.96

$9,923.20
$4,504.01
72
$12184.60
$1,394.43
$65,318.57

Total
$2,452.64
$6,787.73
$1,455.55
$3,623.07
353
353
$4,155.20
$12167.39
$267.06
$546.48
$59,404.03 $167,658.82
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Figure 3: Antibiotic Use and CRP Diagnostic Testing
Antibiotic
Indication
Respiratory

Measures of
Frequency

LOS

Direct Cost

Mean
Median
Sample Size
Standard Deviation
Minimum
Maximum

6.86
5
7
5.728
1
14

$11,915.89
$5,085.43
7
11888.9755
$857.91
$857.91

Mean
Median
Sample Size
Standard Deviation
Minimum
Maximum

2.7
$3,775.40
2
2,006.74
281
281
4.115
$7,948.86
0
$279.42
44 $108,254.78

Indirect
Cost
$5,661.40
$3,112.54
7
$5,187.21
$536.52
$12,924.20

Total Cost
$17,577.29
$8,197.97
7
16871.3902
$1,394.43
$42,738.98

No Antibiotics
$2,208.94
$5,984.34
$1,385.27
$3,398.72
281
281
$267.06 12053.7103
$1,385.27
$546.48
$59,404.03 $167,658.82

Total for All
Indications
Mean
Median
Sample Size
Standard Deviation
Minimum
Maximum

3.03
2
353

$4,335.10
2,115.98
353

4.465
$8,114.17
0
$279.42
44 $108,254.78

$2,452.64
$1,455.55
353

$6,787.73
$3,623.07
353

$4,155.20
$12167.38
$267.06
$546.48
$59,404.03 $167,658.82
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Figure 4: Distribution of Direct Costs
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Figure 5: Distribution of Indirect Costs
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Figure 6: Distribution of Total Costs
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Figure 7: Distribution of Length of Stay
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Figure 8: Length of Stay Measures of Dispersion
Measurement of Dispersion
Minimum
Q1
Median
Q3
Maximum
IQR

Value
0
1
2
3
44
2

Figure 9: Direct Cost Measures of Dispersion
Measurement of Dispersion
Minimum
Q1
Median
Q3
Maximum
IQR

Value
$279.42
$1,408.57
2,115.98
$3,739.98
$108,254.78
$2,331.41

Figure 10: Indirect Cost Measures of Dispersion
Measurement of Dispersion
Minimum
Q1
Median
Q3
Maximum
IQR

Value
$267.06
$954.28
$1,455.55
$2,410.16
$59,404.03
$1,455.87

Figure 11: Total Cost Measures of Dispersion
Measurement of Dispersion
Minimum
Q1
Median
Q3
Maximum
IQR

Value
$546.48
$2,409.29
$3,623.07
$5,993.10
$167,658.82
$3,583.81
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